Table 3.
Measures
| SCREENING | BASELINE | ACTIVE TX | 1M Post-Quit (End of Treatment) | 3M Post-Quit | 6M Post-Quit | |
|---|---|---|---|---|---|---|
| SELF-REPORT | ||||||
| SCREENING AND DESCRIPTIVE MEASURES | ||||||
| Demographics | X | X | ||||
| Screener Questions | X | |||||
| FTND | X | |||||
| SHQ | X | X | ||||
| Motivation to Quit | X | X | ||||
| ASSESSMENT OF ABSTINENCE | ||||||
| TLFB | X | X | X | X | X | |
| ANXIETY AND DEPRESSIVE SYMPTOMS | ||||||
| PHQ8 | X | X | X | X | X | |
| OASIS | X | X | X | X | X | |
| TRANSDIAGNOSTIC MECHANISMS | ||||||
| SSASI | X | X | X | X | X | |
| DTS | X | X | X | X | X | |
| SHAPS | X | X | X | X | X | |
| COST-EFFECTIVENESS | ||||||
| EQ-5D-3L | X | X | X | |||
| Resource Utilization for Cost | X | X | X | X | X | X |
| HIV-RELATED VARIABLES | ||||||
| RUQ | X | X | X | X | ||
| ART Adherence | X | X | X | X | X | |
| ACTG SF-12 | X | X | ||||
| CLINICIAN ADMINISTERED/COMPLETED | ||||||
| MINI | X | |||||
| Therapist Adherence | X | |||||
| BIOLOGICALLY VERIFIED | ||||||
| Carbon Monoxide Analysis | X | X | X* | X* | X* | |
| Saliva Cotinine Analysis * | X* | X* | X* | |||
| Urine Anabasine Analysis * | X* | X* | X* | |||
| Third-party smoking abstinence verification * | X* | X* | X* | |||
| CD4 and Viral Load | X | X | ||||
*
Dependent on a participant’s use/non-use of NRT, participants may complete select biological verifications at follow-ups. Please see page 23 for more details.